The mechanism underlying decreased arginine bioavailability in CF is unknown, but we propose that this deficit worsens the channel function of the low, residual levels of F508del-CFTR and that increased SLC6A14 expression will offset this deficit. Here, SLC6A14 is linked to cystic fibrosis.